U.S. market Closed. Opens in 10 hours 53 minutes

ASLN | ASLAN Pharmaceuticals Limited Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue12.00MN/AN/AN/A3.00MN/AN/A11.49MN/AN/A
Cost of Revenue348.50K331.75K282.22K297.76K407.26KN/AN/A124.37KN/AN/A
Gross Profit11.65M-331.75K-282.22K-297.76K2.59MN/AN/A11.36MN/AN/A
Operating Expenses55.39M47.88M33.85M16.48M48.17M42.35M39.94M20.02MN/AN/A
Selling, General & Admin12.89M9.88M11.83M7.17M8.51M10.51M9.33M6.92M6.61M2.82M
Research & Development42.50M38.00M22.02M9.31M16.59M31.83M30.62M13.10M6.22M4.50M
Other Operating Expenses-11.13K356.56K2.21M758.75K23.07M244.59KN/A0-12.84M-7.31M
Operating Income-43.74M-47.88M-33.85M-16.48M-45.58M-42.35M-39.94MN/A-12.84M-7.31M
Other Expenses / Income-342.75K-3.40M2.26M-487.99K-1.08M176.91K-767.73K-347.67K-486.90K-49.52K
Before Tax Income-44.08M-51.28M-31.59M-16.97M-46.66M-42.17M-40.71M-9.00M-13.33M-7.36M
Income Tax Expenses132.67K99.22K3.12M934.92K408.00K14.44KN/AN/AN/AN/A
Net Income-44.22M-51.38M-34.71M-17.91M-47.07M-42.19M-40.71M-9.00M-13.33M-7.36M
Interest Expenses4.33M3.68M1.86M1.25M901.61K491.90K425.27K521.50K986.93K295.40K
Basic Shares Outstanding16.45M13.95M13.03M7.69M6.50M5.99M24.89M21.03M1.28M1.28M
Diluted Shares Outstanding16.45M13.95M13.03M7.69M6.50M5.99M24.89M21.03M1.28M1.28M
EBITDA-43.39M-47.61M-32.04M-15.72M-45.76M-41.44M-40.07M-8.41M-12.83M-7.28M
EBITDA Margin-361.56%0.00%0.00%0.00%-1,525.20%0.00%0.00%-73.17%0.00%0.00%
EBIT-39.76M-47.61M-29.73M-15.72M-45.76M-41.68M-40.29M-8.48M-12.34M-7.07M
EBIT Margin-331.33%0.00%0.00%0.00%-1,525.20%0.00%0.00%-73.83%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙